18F-FDG-PET and 18F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta-analysis

Journal of Medical Imaging and Radiation Oncology

Volumn 56, Issue 2, 2012, Pages 136-142

  Cheng, Xu ^a   Bao, Lihua ^a   Xu, Zhaoqiang ^a   Li, Dianfu ^a   Wang, Jie ^a   Li, Yongjun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Fluorodeoxyglucose F18; Medullary thyroid carcinoma; Meta analysis; PET; PET CT

Indexed keywords

3 O METHYL 6 FLUORO 3,4 DIHYDROXYPHENYLALANINE F 8; 6 FLUORODOPA F 18; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; METHOXYISOBUTYLISONITRILE I 131; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; HISTOLOGY; HUMAN; META ANALYSIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; MEDULLARY CARCINOMA; PATHOLOGY; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

CARCINOMA, MEDULLARY; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84859793957     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2012.02344.x     Document Type: Review

References (28)

1. Ball DW. Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007; 36: 823-37. (Pubitemid 47126253)
2. Lairmore TC, Wells SA Jr. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol 1991; 7: 92-9.
3. Vitale G, Caraglia M, Ciccarelli A et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001; 91: 1797-808. (Pubitemid 32377967)
4. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163-8. (Pubitemid 38183876)
5. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88: 1139-48. (Pubitemid 30127676)
6. Rufini V, Castaldi P, Treglia G et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008; 62: 139-46. (Pubitemid 351381932)
7. Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2009; 21: 5-10.
8. Wang Q, Takashima S, Fukuda H, Takayama F, Kobayashi S, Sone S. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 1999; 125: 842-8. (Pubitemid 29372802)
9. Naji M, Hodolic M, El-Refai S et al. Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management. J Endocrinol Invest 2010; 33: 54-60.
10. Szakáll S Jr, Esik O, Bajzik G et al. 18F-FDG-PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43: 66-71. (Pubitemid 34101190)
11. Bozkurt MF, Uǧur O, Banti E, Grassetto G, Rubello D. Functional nuclear medicine imaging of medullary thyroid cancer. Nucl Med Commun 2008; 29: 934-42.
12. Koopmans KP, de Groot JW, Plukker JT et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008; 49: 524-31. (Pubitemid 351520599)
13. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007; 34: 1604-9. (Pubitemid 47476914)
14. Ong SC, Schöder H, Patel SG et al. Diagnostic accuracy of 18F-FDG-PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48: 501-7. (Pubitemid 47571403)
15. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol 2007; 9: 72-7. (Pubitemid 46336221)
16. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11: 786-94. (Pubitemid 40486694)
17. Diehl M, Risse JH, Brandt-Mainz K et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28: 1671-6. (Pubitemid 33036110)
18. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27: 490-6. (Pubitemid 30262612)
19. Gotthardt M, Battmann A, Höffken H et al. 18F-FDG-PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 2004; 25: 439-43. (Pubitemid 38591103)
20. Jang HW, Choi JY, Lee JI et al. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG-PET/CT. Endocr J 2010; 57: 1045-54.
21. Conry BG, Papathanasiou ND, Prakash V et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 49-57.
22. Marzola MC, Pelizzo MR, Ferdeghini M et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010; 36: 414-21.
23. Skoura E, Rondogianni P, Alevizaki M et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun 2010; 31: 567-75.
24. Rubello D, Rampin L, Nanni C et al. The role of 18F-FDG-PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 2008; 34: 581-6. (Pubitemid 351514892)
25. Oudoux A, Salaun PY, Bournaud C et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007; 92: 4590-7. (Pubitemid 350223431)
26. Giraudet AL, Vanel D, Leboulleux S et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92: 4185-90. (Pubitemid 350074730)
27. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-73.
28. Mirallié E, Vuillez JP, Bardet S et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 779-88. (Pubitemid 40279196)